US Patent 9,663,574 Complement C5 Neutralizing Antibody: Claims, Freedom-to-Operate, and Expiration Timeline
US Patent 9,663,574 centers on a human C5-binding antibody that blocks C5 cleavage into C5a and C5b, with defined CDR sequences and an explicit pharmacokinetic requirement: human serum half-life of at least 40 days. Dependent claims add an engineered Fc domain with FcRn-binding substitutions (Met-429-Leu and Asn-435-Ser in EU numbering), defined variable regions/constant regions, and affinity windows across pH 7.4 vs pH 6.0. The patent’s enforceable scope is driven by the antibody’s CDR sequence identity and functional criteria (C5 cleavage inhibition and pH-dependent binding), not by general C5 inhibition.
What claims define US 9,663,574’s C5 antibody scope?
Claim 1: core protected antibody identity and function
Claim 1 requires all of the following:
- Binding specificity: isolated antibody (or antigen-binding fragment) binds human complement component C5.
- Mechanism: inhibits cleavage of C5 into C5a and C5b.
- CDR sequence requirements (human Ig numbering implied by SEQ ID use in the patent):
- Heavy chain CDR1 = SEQ ID NO:23
- Heavy chain CDR2 = SEQ ID NO:19
- Heavy chain CDR3 = SEQ ID NO:3
- Light chain CDR1 = SEQ ID NO:4
- Light chain CDR2 = SEQ ID NO:5
- Light chain CDR3 = SEQ ID NO:6
- Pharmacokinetics: human serum half-life ≥ 40 days.
Practical implication for scope: design-around paths must avoid at least one of the claim anchors: (i) the exact CDR amino-acid identities, (ii) the half-life threshold, or (iii) the combination of C5 cleavage inhibition plus C5 binding to the relevant epitope consistent with those CDRs. If a competitor antibody uses different CDRs but still inhibits C5 cleavage and has similar half-life, it may avoid literal infringement but could still face doctrine-of-equivalents theories depending on claim construction in the relevant litigation forum.
Claim 2: FcRn-engaging Fc engineering
Claim 2 adds a variant human Fc that binds FcRn, with specific substitutions:
- Met-429-Leu and Asn-435-Ser at EU-numbered residues corresponding to methionine 428 and asparagine 434.
This is a tighter constraint than generic Fc engineering. It targets antibodies engineered for longer circulation via FcRn engagement.
Claims 3 and 4: variable-region and constant-region definitions
- Claim 3: heavy variable region = SEQ ID NO:12; light variable region = SEQ ID NO:8.
- Claim 4: heavy chain constant region = SEQ ID NO:13.
These make the claim narrower than “CDR-only” embodiments because they lock in broader variable-region context and Fc class.
Claim 5: full heavy/light polypeptide sequences
- Heavy chain polypeptide = SEQ ID NO:14
- Light chain polypeptide = SEQ ID NO:11
This is the most restrictive form of identity: if those entire polypeptides are not used, literal infringement becomes difficult.
Claims 6 to 8: pH-dependent binding affinity windows
Claim 6 specifies a tight high affinity at pH 7.4:
- pH 7.4, 25°C: 0.1 nM ≤ Kd ≤ 1 nM
Claim 7 specifies weaker binding at pH 6.0:
Claim 8 ties them:
- (Kd at pH 6.0) / (Kd at pH 7.4) > 25
What this means technically: the claim requires a marked pH-dependent reduction in C5 binding, consistent with an antibody that binds strongly at physiological pH but weakly in acidic compartments (which can correlate with FcRn or endosomal processing). Even if an antibody matches CDR sequences, failing the pH dependence or the Kd ranges can defeat literal infringement.
Claims 9 and 10: downstream product claims
- Claim 9: pharmaceutical composition containing the claimed antibody plus carrier.
- Claim 10: therapeutic kit containing the antibody and instructions.
These do not expand the core antibody scope; they inherit it.
How many independent “infringement levers” does US 9,663,574 create?
US 9,663,574 is structured with multiple layers. A product must satisfy:
- CDR identity set (six CDRs across heavy and light chains) and
- C5 cleavage inhibition function and
- human serum half-life ≥ 40 days,
and if asserted under dependent claims:
- FcRn-binding Fc substitutions (Met-429-Leu; Asn-435-Ser), and/or
- specific pH-dependent C5 affinity (Claims 6-8), and/or
- specific full variable/constant sequences (Claims 3-5).
This layered drafting reduces the risk that a “close” C5 blocker avoids infringement merely by changing one property. For an alleged infringer, the main path is to diverge from the CDR sequence identity rather than only adjusting PK or affinity.
What patents protect C5 cleavage inhibitors with engineered half-life Fc domains in the US?
A complete “how many patents” analysis requires the full patent family of US 9,663,574 and the surrounding Continuation/Divisional/Continuation-in-Part records, plus the broader C5 inhibitory antibody landscape in the US. That information is not present in the input provided here.
When does US 9,663,574 lose exclusivity and what is the practical launch window?
A complete exclusivity timeline requires:
- the priority filing date,
- whether the asserted claims are tied to an application filed under a specific post-2013 regime,
- any PTE/PTE availability, and
- whether patent term adjustments/extendable components apply.
None of those dates are provided in the input. Without them, generating a reliable expiration date timeline would be incomplete.
What does the claim set suggest about likely enforcement posture and claim construction?
CDR-sequence anchoring narrows literal infringement
Because Claim 1 specifies multiple CDR amino-acid sequences by SEQ ID number, literal infringement hinges on sequence matching (or exact equivalents if the claim is construed that way under the doctrine of equivalents).
Functional constraints add independent non-sequence risk
Even sequence-matching antibodies may not satisfy:
- C5 cleavage inhibition into C5a/C5b, and
- the half-life ≥ 40 days threshold.
That means a competitor could potentially map CDRs but still avoid infringement if pharmacokinetics and functional blockade do not align with the claim language as construed.
pH-dependent affinity windows add a measurable QC barrier
Claims 6-8 create a testable property set. If accused products show a similar C5 binding at pH 7.4 but do not lose binding at pH 6.0 with the required magnitude, the dependent claim may fail.
FcRn substitutions limit dependent-claim coverage
The FcRn variant described in Claim 2 is narrow. Competitors using different FcRn-binding mutations may avoid that dependent claim while still potentially infringing Claim 1 if they match the CDRs and half-life requirement.
How does US 9,663,574 likely compare with current C5-targeting antibody strategies?
The broader market uses C5 inhibition modalities that typically include:
- antibodies that bind C5 and prevent MAC formation and/or C5 cleavage,
- engineered antibodies designed for long systemic exposure (often via FcRn recycling), and
- sometimes small molecules (less common in C5 cleavage inhibition).
US 9,663,574’s distinguishing feature is the combination of:
- fixed six CDR identities,
- explicit serum half-life ≥ 40 days, and
- explicit pH-dependent binding behavior (for dependent claims).
That combination tends to align with a program that intentionally optimizes both efficacy and residence time.
What is the Orange Book status or FDA regulatory linkage of US 9,663,574?
A mapping to Orange Book requires:
- the specific drug name(s) tied to the patent,
- NDA/BLA identifiers, and
- listing records.
No FDA regulatory identifiers are provided in the input, so no accurate Orange Book status can be stated.
Paragraph IV and biosimilar risk: what would trigger litigation exposure?
A correct assessment requires the following:
- which product(s) are covered by US 9,663,574 in FDA listings,
- whether any Paragraph IV notice has been filed,
- whether there are settled cases affecting launch timing,
- whether any biosimilar route is relevant (C5 inhibitors are often monoclonal antibodies, but biosimilar applicability depends on whether the biologic is in the reference product ecosystem).
Those inputs are not provided.
Key Takeaways
- US 9,663,574 protects a specific C5-binding, C5 cleavage-inhibiting antibody defined by six CDR sequence identities plus a human serum half-life ≥ 40 days requirement in Claim 1.
- Dependent claims tighten protection through FcRn-binding Fc mutations (Met-429-Leu; Asn-435-Ser), defined variable/constant sequences, and pH-dependent Kd windows (strong binding at pH 7.4 and weak binding at pH 6.0 with a ratio constraint).
- The most credible design-around to avoid literal infringement is changing the CDR sequences so they no longer match the specified SEQ ID-defined CDRs; altering only Fc or only binding affinity is not enough if Claim 1’s anchored sequence and functional requirements are met.
- A complete landscape review for expirations, FDA status, and litigation/Paragraph IV exposure cannot be derived from the provided claim text alone.
FAQs
- What parts of US 9,663,574 are most likely to determine literal infringement: CDR sequences or pH-dependent Kd values?
- If an antibody matches the CDRs but has human half-life under 40 days, does it avoid Claim 1?
- How do Met-429-Leu and Asn-435-Ser substitutions affect potential infringement of FcRn-engineered variants?
- What experimental assays are typically used to prove “inhibits cleavage of C5 into C5a and C5b” for claim infringement?
- What design-around strategy is most effective against a claim that combines CDR identity with mechanistic function and serum half-life thresholds?
References
- United States Patent 9,663,574, claims 1-10 (as provided in prompt).
